ARRY Overview
Upcoming Projects (ARRY)
-
Don’t see a project related to the company you care about? Create your own!
Upcoming & Overdue Catalysts (ARRY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ARRY)
-
PDUFA set to June 30, 2018 for both applications of Binimetinib And Encorafenib in Advanced BRAF-mutant Melanoma
Ticker: ARRY
Occurred on: Jun 27, 2018 -
Array's (ARRY) NDA for Binimetinib (GX818/MEK162/LGX818) in BRAF Mutant Melanoma (COLUMBUS) Planned for mid 2017
Ticker: ARRY
Occurred on: Jul 05, 2017 -
Array Bio (ARRY) Withdraws NDA for Binimetinib (MEK162) in NRAS Mutation-Positive Melanoma
Ticker: ARRY
Occurred on: Mar 20, 2017 -
Array Bio (ARRY) and Pierre Fabre Announces PHASE 3 COLUMBUS Results Evaluating LGX818 + MEK162 in Melanoma
Tickers: ARRY, Pierre Fabre
Occurred on: Sep 26, 2016 -
Array BioPharma Announces FDA Acceptance of Binimetinib NDA for Patients with Advanced NRAS-Mutant Melanoma
Ticker: ARRY
Occurred on: Sep 01, 2016 -
Array Presents Data from Cardiovascular Trial with ARRY-797 at the European Society of Cardiology Congress
Ticker: ARRY
Occurred on: Aug 30, 2016 -
Selumetinib did not meet trial endpoint of progression-free survival in KRASm NSCLC patients
Tickers: AZN, ARRY
Occurred on: Aug 09, 2016 -
Array BioPharma Submits Binimetinib New Drug Application to U.S. FDA
Ticker: ARRY
Occurred on: Jun 30, 2016 -
Array Presents Full Results from Phase 3 NEMO Study
Ticker: ARRY
Occurred on: Jun 06, 2016 -
Array BioPharma Announces Decision To Discontinue MILO Study In Ovarian Cancer
Ticker: ARRY
Occurred on: Apr 01, 2016 -
Array Discontinues Phase 3 MILO Trial Evaluating MEK162 (ARRY-162) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
Ticker: ARRY
Occurred on: Apr 01, 2016
Strategic Initiatives (ARRY)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
